BetterLife Pharma - CEO, Ahmad Doroudian.
CEO, Ahmad Doroudian.
Source: BetterLife Pharma.
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • BetterLife’s (BETR) wholly-owned subsidiary, Altum Pharmaceuticals has secured a financing commitment from a strategic investor
  • It has signed an agreement with a European-based investor group to complete a non-brokered financing of up to US$5.0 million
  • The investor group will own approximately 12.5 per cent of Altum’s issued and outstanding shares
  • BetterLife Pharma Inc. is an emerging biotechnology company engaged in the development and commercialization of next generation psychedelic products
  • BetterLife Pharma Inc. (BETR) is up 12.50 per cent, trading at C$0.22 at 1:09 pm EST

BetterLife Pharma (BETR) subsidiary Altum Pharmaceuticals will complete non-brokered financing of up to US$5.0 million with a European-based investor group.

The financing will be in tranches and will commence in January of 2022. At the completion of the US$5.0 million financings, the investor group will own approximately 12.5 per cent of Altum’s issued and outstanding shares.

“BetterLife has also formed a special committee to explore strategic options available to BetterLife and Altum in connection with the advancement of their respective programs,” said BetterLife’s Chief Executive Officer, Dr. Ahmad Doroudian.

“Shareholders of BetterLife will receive shares of Altum directly through a dividend or other similar form of distribution and will continue to participate in the growth of both companies while allowing BetterLife and Altum to focus on their respective business segments,” added Doroudian.

BetterLife Pharma Inc. is an emerging biotechnology company engaged in the development and commercialization of next-generation psychedelic products for the treatment of mental disorders.

BetterLife Pharma Inc. (BETR) is up 12.50 per cent, trading at C$0.22 at 1:09 pm EST.

More From The Market Herald

" Medicenna (TSX:MDNA) announces publication of MDNA11 preclinical data

Medicenna Therapeutics Corp. (MDNA) announced the publication of preclinical data on MDNA11.

" Clearmind Medicine (CSE:CMND) engages the Independent Trading Group as a market maker and Thunder11 as a PR agency

Clearmind Medicine Inc. (CMND) has engaged the services of Independent Trading Group to provide market-making services.

" Psyched Wellness (CSE:PSYC) provides update on study with the National Research Council of Canada

Psyched Wellness (PSYC) has released preliminary data from its study with the National Research Council of Canada (NRC).
codikoat, covid protection

" PharmaDrug (CSE:PHRX) begins manufacturing PD-001 for treatment of rare cancers and COVID-19

PharmaDrug (PHRX) has begun manufacturing PD-001, its oral formulation of cepharanthine, for cancer and infectious disease studies.